Bilex Pharma is pleased to announce the launch of Project SHIELD, a comprehensive initiative focused on developing next-generation vaccines against major respiratory viral pathogens. This strategic program integrates the company’s most advanced clinical candidates with innovative research efforts aimed at transforming the prevention of respiratory viral diseases. A Unified Approach to Respiratory Viral Threats Project…

Continue Reading

Bilex Pharma is pleased to announce that BLX-TB01, our novel tuberculosis (TB) vaccine candidate, has received regulatory approval to begin Phase 1 clinical trials. This milestone marks a significant advancement in the company’s efforts to develop an effective vaccine against one of the world’s deadliest infectious diseases. Addressing a Persistent Global Health Challenge Tuberculosis remains…

Continue Reading

Bilex Pharma is proud to announce that our innovative mRNA technology platform has been featured in a peer-reviewed article published in the prestigious journal Nature Biotechnology. The publication highlights the company’s proprietary BiLipid™ delivery system and SAMplify™ self-amplifying mRNA platform, showcasing advances that could significantly enhance mRNA vaccine performance. Groundbreaking Research Recognized in Leading Scientific…

Continue Reading

Bilex Pharma is pleased to announce the official opening of its new Technical Operations Centre in Glasgow, Scotland, marking a significant expansion of the company’s UK-based capabilities and strengthening its commitment to building integrated vaccine development and manufacturing expertise within the United Kingdom. Strategic Investment in Scottish Innovation The 5,200 square meter facility, located at…

Continue Reading

Bilex Pharma is proud to announce its membership in the newly formed Global Antimicrobial Resistance (AMR) Vaccine Consortium, a groundbreaking international initiative dedicated to developing innovative vaccines against drug-resistant pathogens. This strategic collaboration brings together leading academic institutions, pharmaceutical companies, and global health organizations in a coordinated effort to address one of the most pressing…

Continue Reading

Bilex Pharma is pleased to announce positive Phase 2 clinical trial results for BLX-RSV01, our investigational vaccine candidate for Respiratory Syncytial Virus (RSV). The trial demonstrated robust immune responses in adults aged 60 and older, a population particularly vulnerable to severe RSV disease. Trial Results Exceed Expectations The randomized, placebo-controlled Phase 2 study enrolled 350…

Continue Reading

Bilex Pharma is pleased to announce the successful completion of a £50 million Series B funding round to accelerate the development of its innovative vaccine pipeline and expand its UK operational capabilities. Strategic Investment to Fuel Growth The funding round was led by Oxford Science Enterprises, with significant participation from Cambridge Innovation Capital, SR One,…

Continue Reading

Bilex Pharma is proud to announce the official inauguration of our new Oxford Scientific Operations facility, a state-of-the-art research center that marks a significant expansion of our UK operations and reinforces our commitment to advancing vaccine science. Strategic Expansion in the Golden Triangle Located at the Oxford Science Park, this 3,500 square meter facility represents…

Continue Reading